One of the strategies to circumvent this problem, involves the use of CARs with single chain variable fragments (scFvs) of lower affinity, generated through “light-chain exchange technology.” These low-affinity CD38 CAR-T cells are able to kill CD38high MM cells, while having no effect on the viability of CD38low healthy cells, as validated both in vitro and in vivo (59). Here, CD38 is linked to Miyoshi myopathy.